Showing 1 - 10 of 9,579
Persistent link: https://www.econbiz.de/10014441342
Persistent link: https://www.econbiz.de/10001236764
Persistent link: https://www.econbiz.de/10012035670
companies does not pose a sufficient risk of harm to innovation to justify a regulatory or antitrust requirement of open access …
Persistent link: https://www.econbiz.de/10014207431
has allegedly reduced innovation by refusing to deal with the plaintiffs. We note that claims of reduced innovation are …
Persistent link: https://www.econbiz.de/10014207444
Persistent link: https://www.econbiz.de/10012656321
Persistent link: https://www.econbiz.de/10012507173
Constantly rising expenditures for pharmaceuticals require government intervention in firms' pricing decisions. To this end, reference pricing systems are a frequently employed regulatory mechanism. This paper considers a duopoly market with vertically differentiated firms under different...
Persistent link: https://www.econbiz.de/10011976973
Persistent link: https://www.econbiz.de/10011977613
Persistent link: https://www.econbiz.de/10011981039